"CHEMIMMUNE THERAPEUTICS" LIMITED LIABILITY COMPANY
发明人:
Vladimir Evgenievich NEBOLSIN,Anastasia Vladimirovna RYDLOVSKAYA
申请号：
US16644899
公开号：
US20200188379A1
申请日:
2018.03.06
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The invention relates to medicine and concerns the treatment of diseases related to the aberrant activity of fractalkine and monocyte chemoattractant proteins 1-4 (CCL2, CCL7, CCL8, CCL13), preferably the treatment of pain, fever, pneumonia, bronchitis, bronchiolitis, alveolitis, rheumatoid arthritis, psoriasis and other diseases, using the compound 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dioneor a pharmaceutically acceptable salt or solvate thereofThe present invention also relates to pharmaceutical compositions that contain a therapeutically effective amount of the claimed compound according to the invention. The present compound and pharmaceutically acceptable salts thereof are highly effective in inhibiting the activity of the glutaminyl cyclase enzyme, which is involved in particular in processes of post-translational modification of the above-mentioned cytokines.
